CAMK2G and medullary thyroid gland carcinoma: Notably, the clinical severity of MTC is negatively correlated with the expression level of hCaKIINα, an endogenous inhibitor of CaMKII [125], suggesting its potential as a biomarker and therapeutic target for MTC.